Clinical Trial - Trial jRCT2031230109
Access comprehensive clinical trial information for jRCT2031230109 through Pure Global AI's free database. This phase not specified trial is sponsored by Eli Lilly Japan K.K. and is currently Recruiting. The study focuses on Breast Neoplasms.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
jRCT2031230109
Recruiting
Trial Details
Japan Registry Clinical Trial • jRCT2031230109
Untitled Trial
EMBER 4: A Randomized, Open Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2 Early Breast Cancer With an Increased Risk of Recurrence (J2J MC JZLH)
Study Focus
Interventional
Sponsor & Location
Eli Lilly Japan K.K.
Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech;Finland;France;Germany;Greece;China;Hu
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Malignant neoplasm of breast
Malignant neoplasm of breast
Malignant neoplasm: Breast, unspecified
Benign neoplasm of breast
Malignant neoplasm: Central portion of breast
Data Source
Japan Registry Clinical Trial
jRCT2031230109
Non-Device Trial